London · Delayed Price · Currency is GBP · Price in USD Palatin Technologies Company Description
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States.
It is developing oral small molecule PL7737 agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity completed Phase 2 clinical trial; completed a phase 2 of diabetic nephropathy It also provides pl9643 for dry eye disease; and oral PL8177 for inflammatory bowel diseases.
licensing arrangements and other strategic transactions to advance and maximize the value of certain product candidates and program for the treatment of retinal diseases and with Altanispac Labs for PL9643 for the treatment of dry eye disease; and oral PL8177 for the treatment inflammatory bowel diseases.
Palatin Technologies, Inc. was incorporated in 1986 and is based in Princeton, New Jersey.
| Country | United States |
| Founded | 1986 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 25 |
| CEO | Carl Spana |
Contact Details
Address: 301 Carnegie Center Drive Princeton, New Jersey 08540 United States | |
| Phone | 609 495 2200 |
| Website | palatin.com |
Stock Details
| Ticker Symbol | 0KF3 |
| Exchange | London Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| ISIN Number | US6960776010 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Carl Spana Ph.D. | Co-Founder, President, Chief Executive Officer and Director |
| Stephen T. Wills CPA, MST | Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer and Secretary |
| Burns McClellan | Vice President of Investor Relations |
| Stephen A. Slusher Esq. | Chief Legal Officer |
| Dr. Michael B. Raizman M.D. | Chief Medical Officer |
| James E. Hattersley B.A., M.S. | Senior Vice President of Business Development |
| John Dodd Ph.D. | Senior Vice President of Preclinical Development |
| Robert Jordan | Senior Vice President of Program Operations |